Truist Securities has revised several stock ratings, raising targets for Jazz Pharmaceuticals and nCino based on clinical approvals and strong performance, while lowering its outlook for Intuit due to cautious guidance. The adjustments highlight shifting investor sentiment across healthcare, fintech, and software sectors.
Multiple investment firms, including DA Davidson, H.C. Wainwright, Stifel, TD Cowen, Wolfe Research, and JPMorgan, have reiterated or initiated stock ratings for various companies. These ratings are based on strong financial results, trial enrollments, earnings outlooks, and market developments.
RBC Capital Markets has increased price targets for several software stocks, including Snowflake and CrowdStrike, in anticipation of their upcoming earnings reports.
Amrize has been downgraded by RBC Capital, with analysts noting that despite rising volumes, the company is experiencing a lack of corresponding margin growth. This assessment suggests concerns about profitability despite increased activity.
According to RBC Capital Markets' Frances Donald, underlying inflation pressures persist, casting a shadow over the Federal Reserve's economic outlook and policy decisions.
Several financial institutions, including BofA, RBC Capital, Bernstein, Morgan Stanley, and Truist, have increased their price targets for various companies. These companies include Amazon.com, Tesla, ASML Holding, Lam Research, KLA, and Amgen.
RBC Capital Markets has initiated coverage on Centene (CNC), expressing a positive outlook and suggesting that the company's challenges from 2025 are now behind it.
RBC Capital has significantly increased its price target for Micron Technology (MU) by $675, explaining the rationale behind this substantial revision. This reflects a bullish sentiment regarding the memory and storage solutions provider.
RBC Capital reports that Nike's business turnaround is progressing slower than anticipated, indicating the company is still struggling to gain momentum.
RBC Capital has increased its price target for Albemarle (ALB) to $257, while reiterating an 'Outperform' rating on the stock. This indicates a continued positive outlook from the firm for the chemical company.
RBC Capital Markets has increased its price target for Marvell Technology stock, citing strong performance and future growth prospects. This adjustment reflects a positive outlook from the investment bank.
RBC Capital has reaffirmed its 'Outperform' rating on Emerson Electric (EMR), maintaining a positive outlook despite economic headwinds from the Middle East.
RBC Capital has trimmed the price target for Lowe’s Companies (LOW) by $32. This adjustment reflects a revised valuation for the home improvement retailer.
RBC Capital Markets upgraded an unnamed steakhouse chain to outperform, citing increased restaurant traffic and declining beef prices as positive indicators for the sector.
Financial analysts have updated their price targets for two companies: Roth Capital raised its target for Coeur Mining, while RBC Capital lowered its target for Kratos Defense & Security Solutions, Inc. RBC Capital maintained an "Outperform" rating for Kratos.
RBC Capital has lifted its price target for CG Oncology (CGON), citing PIVOT-006 as a complex catalyst, and also raised its price target for Acadia Healthcare Company (ACHC) following its Q1 earnings beat.
According to RBC Capital, Shopify is projected to continue growing at a faster rate than the overall U.S. e-commerce market, indicating strong performance for the platform.
RBC Capital has reiterated its positive outlook on Artisan Partners Asset Management (APAM) in anticipation of the company's first-quarter earnings report.
RBC Capital Markets has increased its price target for Vertex Pharmaceuticals (VRTX) as it updates its outlook for the biotech sector. This reflects a positive analyst sentiment towards the company.
Reed Hastings, co-founder of Netflix, is stepping down from his role as chairman after 29 years with the company. His departure marks a significant leadership change for the streaming giant, with some reports noting a drop in stock value following the announcement.
RBC Capital Markets has reduced its price target for UBS while simultaneously adjusting its assumptions regarding the bank's Assets Under Management (AUM).
Global stock markets, oil futures, and specific company performances are experiencing volatility, while geopolitical uncertainty rises, following developments in the Middle East conflict and former President Donald Trump's statements regarding Iran. Economic forecasts for the war and economy range from bad to much worse, and family offices are stalling deal-making due to the conflict, though megadeals continue.
RBC Capital Markets has maintained its Outperform rating on Union Pacific (UNP), while also flagging higher Q1 EPS and potential approval risks for the railway company.
JPMorgan has increased its price target for Edison International (EIX) from $66 to $74, reflecting a positive adjustment in its valuation of the utility holding company.
Investment firms RBC Capital and Jefferies have reiterated their bullish ratings on Microsoft (MSFT), signaling continued confidence in the technology giant's stock performance.
RBC Capital has increased its price target for APA, citing strong oil prices and positive earnings momentum as key factors supporting the company's shares.
RBC Capital Markets has raised its price target for Broadcom (AVGO), citing bullish commentary regarding the company's financial outlook for fiscal year 2027.
RBC Capital has lowered its target price on Fidelity National Information Services (FIS) to $69, following a slight miss in its fourth-quarter earnings.
Multiple financial institutions have updated their price targets and ratings for various companies, reflecting new outlooks on their performance and market conditions.
Ares Management Corporation is scheduled to present at the 2026 RBC Capital Markets Global Financial Institutions Conference, likely to discuss its financial performance and outlook.
RBC Capital Markets has downgraded Imperial Oil, citing that the company's valuation has become 'stretched' following several years of strong stock performance.
Analysts are bullish on several biotech companies, including GH Research, Cybin D/B/A Helus Pharma, and COMPASS Pathways, following a psychedelics symposium and positive model updates, with Baird lowering Bright Minds Biosciences' price target but maintaining an Outperform rating.
RBC Capital Markets has given Atlassian an outperform rating, pointing to sustained upward momentum and strong technical indicators following the stock's recent rally.
Several financial institutions have adjusted their stock price targets for various companies, including Marvell, Advance Auto Parts, Walmart, Ross Stores, MPLX, and Hershey, based on recent earnings, market performance, and sector outlooks.
Analysts from Barclays and RBC Capital Markets predict that European defense company stocks will continue to grow rapidly in the coming years, as the region enters a new phase of increased defense spending.
Lori Calvasina, head of US equity strategy at RBC Capital Markets, discusses current stock market sentiment, noting investor nervousness but no signs of panic.
RBC Capital Markets has initiated coverage on NiSource with an Outperform rating, highlighting Indiana as one of the best data center markets in the Midwest.
RBC Capital has raised its price target on F5 (FFIV), HSBC on Zoom (ZM), JPMorgan on Old Dominion Freight Line (ODFL), and UBS on J. M. Smucker (SJM). These adjustments indicate increased confidence in the future performance of these companies.
According to RBC Capital, Newmont (NEM) is trading at a premium valuation compared to its peers within the gold equities sector. This assessment highlights its strong market position.
RBC Capital Markets predicts that any potential pullback in the S&P 500 index is likely to be limited to a range of 5% to 10%, offering a cautious outlook on market volatility.
RBC Capital analysts have increased their price target for Jacobs Solutions (J) shares to $169, reflecting a positive assessment of the company's performance.
RBC Capital has assigned a "Buy" rating to Wix (WIX), indicating a positive outlook for the company's stock. This recommendation suggests potential for growth for investors.
Citi and RBC Capital analysts have noted improving broadband trends for Comcast (CMCSA), indicating a positive outlook for the company's internet services.
RBC Capital Markets has upgraded its rating for Unilever (UL) stock from its previous position to 'Sector Perform'. This change reflects a revised outlook on the consumer goods giant's market performa
RBC Capital has raised its price target for Incyte Corporation (INCY) from $92 to $95. This upward adjustment reflects a more positive financial outlook for the biopharmaceutical company.
RBC Capital Markets has adjusted its price targets for several companies, trimming Procter & Gamble's target due to modest growth while lifting Chevron's target as its commodity view improves.
RBC Capital has lowered its price target for Autoliv from $141 to $137 and for Dauch Corporation from $10 to $9. These adjustments reflect updated financial outlooks for both companies.
RBC Capital has reiterated its 'Outperform' rating for Wave Life Sciences (WVE), indicating a continued positive outlook on the biotechnology company's stock.
RBC Capital has increased its price target for Nutrien (NTR) in anticipation of the company's first-quarter earnings report. The adjustment is attributed to strong fertilizer prices, signaling positive expectations for Nutrien's performance.
Baird, a financial services firm, has reduced its price target for Nyxoah SA (NYXH) shares from $5.87 to $4.62. This adjustment reflects a revised outlook on the company's financial performance or market conditions.
RBC Capital Markets has increased its stock price target for Canadian National (CN) for the year 2027, indicating a positive outlook for the railway company.
RBC Capital Markets has issued a note indicating that CareTrust REIT, Inc. (CTRE) is well-positioned, even amid increased general and administrative expenses and investment timing considerations.
Several financial institutions have updated their price targets for a range of companies, including CytomX Therapeutics, Upwork, Coursera, Tripadvisor, and The Wendy's Company, while maintaining various ratings.
RBC Capital Markets has identified and named its top investment pick within the business services sector. This recommendation provides guidance for investors looking at opportunities in this market segment.
RBC Capital has reaffirmed its Outperform rating for Verastem (VSTM), indicating continued confidence in the company's stock performance. This reiteration suggests a positive outlook from the financial institution.
RBC Capital has increased its price target on Rackspace Technology (RXT), citing specific reasons for its optimistic outlook. This adjustment reflects the firm's updated analysis of the company's financial performance and market position.
RBC Capital has maintained its Outperform rating on Carvana (CVNA), and William Blair has kept its Outperform rating on Medline (MDLN) following a warehouse fire.
RBC Capital Markets highlights that Varonis Systems' emphasis on data security and governance is becoming increasingly crucial in the evolving landscape of the artificial intelligence era.
RBC Capital has maintained its 'Outperform' rating on Equinox (EQX), signaling continued confidence in the real estate investment trust's stock performance.
RBC Capital Markets has established the highest price target for Astera Labs (ALAB) stock, with an accompanying analysis on how investors can capitalize on the memory trade.
RBC Capital has reiterated its 'Outperform' rating and an $810 price target for Meta Platforms (META), citing an explosion in AI-enabled entrepreneurialism as a key driver.
RBC Capital has announced that it is resuming its coverage of Danaher Corporation (DHR), a move that often signals renewed analyst interest in the company.
Mosaic, a leading producer of phosphate and potash, received an upgrade from RBC Capital, which expressed optimism that challenges in the phosphate market would not persist indefinitely.
RBC Capital has increased its year-end target for the S&P 500 to 7,900, citing optimism surrounding artificial intelligence as a key driver for further market upside.
RBC Capital has increased its price target for BioCryst Pharmaceuticals (BCRX) as part of its preview of Q1 2026 results in the biotech sector. This adjustment reflects RBC Capital's updated outlook on the company's financial prospects.
RBC Capital Markets has maintained its Outperform rating on Linde plc (LIN), indicating continued confidence in the company's financial performance and stock potential.
Financial analysts are releasing Q1 earnings previews for numerous companies, including Amkor Technology and Bed Bath & Beyond. Additionally, several firms are updating price targets and ratings for companies such as Chipotle, Robinhood, and Block.
RBC Capital Markets has slightly trimmed its price target for ACADIA Pharmaceuticals, citing seasonal biotech headwinds. The firm also cut its price target for Galapagos NV to $28, while maintaining a Sector Perform rating ahead of its Q1 earnings.
RBC Capital Markets has reiterated its 'Outperform' rating for Merck (MRK), acknowledging investor concerns regarding a 'modest premium' but maintaining a positive outlook for the pharmaceutical company.
Wall Street analysts have released new research calls, including initiations, upgrades, and price target adjustments for various companies, with the latest reports detailing Wednesday's analyst upgrades and downgrades and highlighting energy firms like Chevron, Kinder Morgan, and TC Energy.
RBC Capital Markets has reiterated its Outperform rating for Nike (NKE), indicating a positive outlook and seeing a clear path to growth for the sportswear giant.
RBC Capital Markets has lowered the price target for Sweetgreen, Inc. (SG) due to a same-store sales outlook that is trailing behind consensus estimates.
RBC Capital lifts CubeSmart's target, Morgan Stanley boosts Fifth Third Bancorp's target, and Morgan Stanley also raises Huntington Bancshares' target, citing banking sector tailwinds.
Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.
Several financial firms, including Morgan Stanley, Truist, RBC Capital, Goldman Sachs, and Scotiabank, have updated their price targets and ratings for companies like Edison International, Vulcan Materials, Global Payments, Insulet, Quanta Services, A. O. Smith, FirstEnergy, and Targa Resources.